{
    "organizations": [],
    "uuid": "533888736788aaf95d349b39e9cf34c038e81689",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-teva-confirms-september-pdufa-date/brief-teva-confirms-september-pdufa-date-for-fremanezumab-idUSFWN1SU0S7",
    "ord_in_thread": 0,
    "title": "BRIEF-Teva Confirms September PDUFA Date For Fremanezumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA CONFIRMS SEPTEMBER PDUFA DATE FOR FREMANEZUMAB * TEVA PHARMACEUTICAL INDUSTRIES LTD - PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR FREMANEZUMAB IS SET FOR SEPTEMBER 16\n* TEVA PHARMACEUTICAL INDUSTRIES - CONFIRMED THAT FDA EXTENDED GOAL DATE OF BLA FOR FREMANEZUMAB Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-23T20:32:00.000+03:00",
    "crawled": "2018-05-24T20:42:10.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "teva",
        "confirms",
        "september",
        "pdufa",
        "date",
        "fremanezumab",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "action",
        "date",
        "fremanezumab",
        "set",
        "september",
        "teva",
        "pharmaceutical",
        "industry",
        "confirmed",
        "fda",
        "extended",
        "goal",
        "date",
        "bla",
        "fremanezumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}